Top stories in hematology/oncology: Deadly subtype makes up 17% of metastatic prostate cancer, American Cancer Society creates blueprint to reduce cancer mortality

Among the top stories in hematology/oncology is study data showing a particularly deadly subtype of prostate cancer occurs in 17% of metastatic, castration-resistant prostate cancer. Researchers from the American Cancer Society identified trends in disparities and outcomes for cancer over several decades to stress the need for better care. Other top stories include a $20 million grant received by the Henry Ford Cancer Institute to fund the creation of a new multi-institutional pancreatic cancer research consortium, clonal hematopoiesis-related mutation appeared to be misinterpreted as solid-tumor mutations when tumor-only sequencing was used, and the addition of ovarian suppression to tamoxifen lengthened overall survival and disease-free survival among premenopausal women with breasted cancer.

Deadly subtype makes up 17% of metastatic prostate cancers

Treatment-emergent small cell neuroendocrine prostate cancer, a particularly deadly subtype of the disease, occurs in nearly one-fifth of all cases of metastatic, castration-resistant prostate cancer, study data showed. Read More.

American Cancer Society creates blueprint to reduce cancer mortality by 2035

Researchers from the American Cancer Society identified trends in disparities and outcomes for cancer over several decades in an effort to highlight the need for better quality care for all individuals with cancer, according to a report published in CA: A Cancer Journal for Clinicians. Read More.

Henry Ford Cancer Institute receives grant to create pancreatic cancer center

The Henry Ford Cancer Institute received a $20 million grant to fund the creation of a new multi-institutional pancreatic cancer research consortium. Read More.

Prevalence of clonal hematopoiesis may confound tumor-only genomic profiling results

Clonal hematopoiesis-related mutations appeared to be misinterpreted as solid tumor mutations when tumor-only sequencing was used for a variety of cancer types, according to results of a gene-sequencing study. Read More.

Ovarian suppression improves 8-year breast cancer survival

The addition of ovarian suppression to tamoxifen lengthened overall survival and disease-free survival among premenopausal women with breast cancer, according to updated findings from the TEXT and SOFT trials published in The New England Journal of Medicine. Read More.